Elanco Animal Health Incorporated (ELAN) Guidance & Earnings Results

On 2026-08-05 Elanco Animal Health Incorporated raised guidance: "Revenue raised to $5.09B-$5.14B, Adj EBITDA raised to $1.01B-$1.035B, Adj EPS raised to…" — from its own filing, as read by EquiReason.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

ELANElanco Animal Health IncorporatedFollow ELAN — free

Drug Manufacturers - Specialty & Generic · Healthcare

—

Price chart with a free account

Market cap: 11.3B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 6 Nov, in 13 days

What management guided

each earnings 8-K · figures checked against the filing text

Release	Direction	What they said
5 Aug 26	Raised	Revenue raised to $5.09B-$5.14B, Adj EBITDA raised to $1.01B-$1.035B, Adj EPS raised to $1.10-$1.16 · full year
6 May 26	Raised	Revenue guidance raised to $5,010M-$5,085M; Adjusted EBITDA to $975M-$1,005M; Adjusted EPS to $1.03-$1.09 · full year
24 Feb 26	Raised	FY2026 revenue $4,950M-$5,020M; Adjusted EBITDA $955M-$985M; innovation target raised to $1.15B
5 Nov 25	Raised	Full-year 2025 revenue guidance raised to $4,645-4,670M; Adjusted EBITDA to $880-900M · full year
7 Aug 25	Raised	FY2025 revenue raised to $4,570-$4,620M from $4,510-$4,580M; FY2025 adjusted EBITDA raised to $850-$890M from $830-$870M; FY2025 adjusted EPS raised to $0.85-$0.91 from $0.80-$0.86; FY2025 innovation revenue target raised by $60M to $720-$800M; FY2025 adjusted gross margin 54.5%-55.0% (up 30 bps); FY2025 net leverage target improved to 3.8x-4.1x; Q3 2025 revenue $1,080-$1,110M; Q3 2025 adjusted EB · full year

Elanco Animal Health Incorporated — questions

What guidance did Elanco Animal Health Incorporated give?: On 2026-08-05: "Revenue raised to $5.09B-$5.14B, Adj EBITDA raised to $1.01B-$1.035B, Adj EPS raised to $1.10-$1.16"
When does Elanco Animal Health Incorporated report earnings?: Elanco Animal Health Incorporated's next earnings report is expected on 2026-11-06.

Every figure on this page comes from Elanco Animal Health Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.